Dyskensia and Parkinson’s Disease

Addex and MJFF Announce Next Step for Dyskensia drug Dipra

Wednesday, 20 March 2013

MJFF and Addex Pharmaceuticals are announcing the next chapter in a continuing partnership around the development of dipraglurant, or “dipra,” for the treatment of dyskinesia, the debilitating side effect of long-term dopamine replacement therapy. A $1-million award from the Foundation will…